Company Historically Provides H-1B Sponsorship
Tempus uses AI and data analytics to improve patient care and accelerate drug development in healthcare. Its proprietary platform analyzes medical data and images to provide actionable insights for physicians and to identify gaps in care, while helping pharma and biotech companies discover targets and evaluate treatments. Cancer research is a focus, including a pan-cancer organoid platform for precision medicine and a liquid biopsy assay to profile circulating tumor DNA. Revenue comes from providing platform access and insights to healthcare providers and industry partners, with the goal of advancing personalized medicine and speeding cancer research.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, IL
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2.9B
Above
Industry Average
Funded Over
18 Rounds
SOTERIA collaborates with Tempus to advance precision oncology for U.S. Military and veterans battling cancer. Nov 09, 2026, 16:39 ET SAN DIEGO, Nov. 9, 2026 /PRNewswire/ - SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt(TM) initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans. Members of the military communities are increasingly being diagnosed with cancer at younger ages and at advanced stages. SOTERIA addresses this critical care gap by providing patient-centric precision oncology navigation and facilitating CLIA-validated germline and somatic sequencing, ensuring that each patient's care is informed by comprehensive molecular data when possible. "Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them," said Julia Civardi, Founder and CEO of SOTERIA. "Partnering with Tempus enables us to bring state-of-the-art genomic sequencing and AI analytics to our active service members and veterans, turning complex molecular data into clear, actionable treatment options for patients and care teams." "Collaborating with SOTERIA allows us to put cutting-edge genomic insights directly into the hands of clinicians and their patients when every decision matters most," said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. "We are proud to support SOTERIA's mission and help advance precision oncology for our nation's service members and veterans." "As a member of the Special Operations community, I've seen the immense toll these cancers take," said CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA. "This initiative reflects the best of what's possible when technological innovation and service come together to support our military families." Through this collaboration, Tempus and SOTERIA will continue to streamline molecular profiling and data integration across SOTERIA's patient cohort, advancing precision oncology research and optimizing care pathways for military community members diagnosed with cancer. CANCER HUNT INQUIRIES MEDIA CONTACTS SOTERIA Media Relations SOURCE SOTERIA Precision Medicine Foundation
Promising Artificial Intelligence stocks to follow now - november 8th. November 8, 2026 Key points. * Hut 8, Tempus AI, and SentinelOne were highlighted as AI stocks with the highest recent dollar trading volume, though the article notes that AI exposure and related risks vary widely across companies. * Hut 8 operates data centers for digital-asset mining and high-performance computing, including AI; its shares rose $6.70 to $52.65 in Friday trading. * Tempus AI applies AI to precision medicine, while SentinelOne provides AI-powered cybersecurity. Their shares also advanced Friday, closing at $76.05 and $21.77, respectively. * MarketBeat previews the top five stocks to own by December 1st. Hut 8, Tempus AI, and SentinelOne are the three Artificial Intelligence stocks to watch today, according to MarketBeat's stock screener tool. Artificial intelligence stocks are shares of companies that develop, provide, or substantially use AI technologies, such as chips, software, cloud services, and AI-powered products. For investors, the term describes a broad theme rather than a formal stock category, and companies' actual exposure to AI - and the risks tied to it - can vary widely. These companies had the highest dollar trading volume of any Artificial Intelligence stocks within the last several days. Hut 8 (HUT). Hut 8 Corp., together with its subsidiaries, acquires, builds, manages, and operates data centers for digital assets mining, computing, and artificial intelligence in the United States. It operates in four segments: Digital Assets Mining, Managed Services, High Performance Computing Colocation and Cloud, and Other. HUT stock traded up $6.70 during mid-day trading on Friday, reaching $52.65. 11,545,992 shares of the stock traded hands, compared to its average volume of 7,015,613. The company has a debt-to-equity ratio of 3.84, a quick ratio of 19.35 and a current ratio of 9.48. The stock has a market capitalization of $6.32 billion, a PE ratio of -10.74 and a beta of 4.53. Hut 8 has a one year low of $31.67 and a one year high of $140.80. The business has a 50-day moving average price of $80.94 and a two-hundred day moving average price of $82.18. Tempus AI (TEM). Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools Shares of TEM stock traded up $5.62 on Friday, hitting $76.05. The stock had a trading volume of 6,279,076 shares, compared to its average volume of 6,385,902. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 3.16. The firm has a market capitalization of $13.72 billion, a P/E ratio of -71.75 and a beta of 3.61. The company's 50 day moving average price is $71.32 and its 200-day moving average price is $57.25. Tempus AI has a 1 year low of $40.77 and a 1 year high of $89.09. SentinelOne (S). SentinelOne, Inc. operates as a cybersecurity provider in the United States and internationally. Its Singularity Platform delivers an artificial intelligence-powered autonomous threat prevention, detection, and response capabilities across an organization's endpoints, cloud workloads, and identify credentials, which enables seamless and autonomous protection against a spectrum of cyber threats. SentinelOne stock traded up $0.35 during trading hours on Friday, hitting $21.77. The stock had a trading volume of 8,790,640 shares, compared to its average volume of 12,371,994. SentinelOne has a 1-year low of $11.81 and a 1-year high of $26.50. The stock has a market capitalization of $7.58 billion, a price-to-earnings ratio of -21.56 and a beta of 0.59. The stock's fifty day moving average is $23.08 and its two-hundred day moving average is $17.83. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Hut 8, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hut 8 wasn't on the list. While Hut 8 currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat
Personalis reported third quarter 2026 sales of $25.6 million and a net loss of $33.8 million, or $0.32 a share from continuing operations. For the first nine months, sales were $63.43 million and the net loss was $95.52 million, or $0.90 a share. The cancer genomics company is being acquired by Tempus for about $1.5 billion, or $16.25 a share. Higher sales show why Tempus wants its MRD and clinical genomics capabilities. Many tests of its NeXT Personal assay are still reimbursed at zero, which keeps cash burn high. Analysts expect revenue to grow 33.4% a year, reaching $165.2 million by 2029, with earnings of $26.8 million.
Tempus AI reported third-quarter 2026 revenue of $411.54 million and a net loss of $14.85 million. It raised its full-year revenue guidance to between $1.60 billion and $1.605 billion. The company signed multi-year data agreements with Bristol Myers Squibb and Pathos AI. Bristol Myers Squibb will license Tempus AI's multimodal oncology data through 2031 and gain access to its Lens platform. Year-to-date data bookings exceed $550 million. The deals give Tempus AI more predictable data and applications income, though reimbursement, competition, and continued losses remain risks. Analysts project revenue of $2.6 billion by 2029, with 22.6% yearly growth.
Tempus AI earnings report: best proven results in Q3. The Tempus AI earnings report reveals that the company has beaten estimates for Q3. This impressive performance highlights the strength of Tempus AI in the current market. Overview of Tempus AI's Q3 performance. Tempus AI has showcased a remarkable performance in its Q3 earnings report, surpassing both earnings and revenue expectations. This quarter marks a significant milestone for the company, reflecting its robust growth trajectory and commitment to innovation in the technology sector. Key highlights from Tempus AI's Q3 performance include: * Earnings per share (EPS): The company reported an EPS that exceeded analyst forecasts, indicating strong profitability. * Revenue growth: Tempus AI achieved a notable increase in revenue compared to the previous quarter, driven by increased demand for its AI-driven solutions. * Market expansion: The company has successfully entered new markets, broadening its customer base and enhancing its competitive edge. Overall, the Tempus AI earnings report reflects a promising outlook and sets the stage for continued success in the upcoming quarters. Key financial metrics. Tempus AI's earnings report for Q3 showcases a strong financial performance that has exceeded expectations. The company reported a revenue of $150 million, marking a 25% increase year-over-year. This growth can be attributed to several key factors, including: * Increased demand for AI-driven healthcare solutions * Expansion into new markets, enhancing service accessibility * Strategic partnerships that have bolstered product offerings Furthermore, Tempus AI's net income for the quarter reached $30 million, up from $20 million in the same period last year. The company's earnings per share (EPS) also surpassed analysts' expectations, coming in at $0.75 compared to the anticipated $0.65. Overall, Tempus AI's earnings report reflects a robust trajectory as the company continues to lead in the AI healthcare sector. Comparison with previous quarters. The Tempus AI earnings report reveals impressive growth when compared to previous quarters. In Q3, the company not only met but exceeded its earnings expectations, showcasing a significant improvement from Q2. This upward trend is attributed to a combination of strategic investments and an expanding customer base. Key comparisons with earlier quarters include: * Q2 Performance: Earnings per share rose by 15% from Q2 to Q3. * Year-over-Year Growth: Revenue increased by 30% compared to Q3 of the previous year. * Quarterly Revenue: Q3 revenue was the highest recorded to date, surpassing all past quarters. Overall, the Tempus AI earnings report illustrates a robust financial trajectory, positioning the company for continued success in the upcoming quarters. Market reaction to earnings. The market reacted positively to the Tempus AI earnings report, with shares of the company experiencing a significant uptick following the announcement. Investors were encouraged by the firm surpassing both earnings and revenue estimates for the third quarter, which highlighted its robust growth trajectory. Analysts noted several factors contributing to the favorable market response: * Strong Revenue Growth: Tempus AI reported a year-over-year increase that exceeded expectations. * Increased Customer Acquisition: The company has successfully expanded its client base, which bodes well for future revenue streams. * Positive Guidance: Management provided an optimistic outlook for the upcoming quarters, further boosting investor confidence. Overall, the earnings report has positioned Tempus AI as a key player in the tech sector, attracting both new and returning investors eager to capitalize on its success. Future outlook for Tempus AI. As Tempus AI continues to build on its recent success, the future outlook appears promising. Analysts are optimistic about the company's ability to leverage its advanced technology in artificial intelligence and data analytics to drive further growth. In the wake of the Tempus AI earnings report, experts predict that the company will expand its market reach and explore new partnerships, enhancing its service offerings. * Strategic Initiatives: Investment in research and development is expected to yield innovative solutions that can cater to evolving market demands. * Market Expansion: Plans to enter new geographic regions may open up additional revenue streams. * Customer Engagement: Enhanced customer service and support are anticipated to improve client retention and satisfaction. Overall, stakeholders are encouraged by Tempus AI's trajectory and potential for sustained success in upcoming quarters. Insights from analysts. Analysts have expressed optimism following the recent Tempus AI earnings report, highlighting the company's strong performance compared to market expectations. Key insights include: * Revenue Growth: Several analysts noted that the revenue growth exceeded forecasts, showcasing Tempus AI's ability to adapt and thrive in a competitive landscape. * Profit Margins: Margin improvements were also highlighted, suggesting effective cost management and operational efficiency. * Market Position: Experts believe Tempus AI is solidifying its market position, making it a strong contender in the tech sector. * Future Potential: The company's innovative solutions are expected to drive further growth, with analysts projecting sustained performance in upcoming quarters. Overall, the consensus among analysts is that Tempus AI's robust third-quarter results signal a promising trajectory for the company. Conclusion and implications. In conclusion, the Tempus AI earnings report for Q3 reveals a strong performance that surpasses analyst expectations. This impressive outcome not only highlights the company's robust operational capabilities but also reflects its strategic positioning in a competitive market. The positive market reaction underscores investor confidence in Tempus AI's growth trajectory and financial health. As the company continues to innovate and expand its offerings, the implications of this earnings report are significant. Analysts predict that the momentum gained in Q3 could lead to sustained growth in the coming quarters. Furthermore, the results suggest that Tempus AI is well-equipped to navigate potential challenges in the tech landscape. Overall, the earnings report serves as a testament to Tempus AI's commitment to excellence and its ability to deliver value to shareholders. The Tempus AI earnings report highlights a significant increase in revenue driven by innovative product offerings. Analysts are optimistic about the future, citing the Tempus AI earnings report as evidence of the company's strong market position.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, IL
Founded
2015
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs